1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

How Sweden's Calliditas Built Up Its US Presence And Development Portfolio

Approval Submission Of Lead Candidate Expected This Quarter

 
• By John Davis

Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.  

View of Gamla Stan in the Old Town of Stockholm
The Old Town Of Stockholm • Source: Shutterstock

Calliditas Therapeutics AB planned the commercialization of its first rare disease product, Nefecon (budesonide), in the US, and expanded its development pipeline through its first major product candidate acquisition , as its coped with last year’s COVID-19-related travel restrictions and changing business processes. 

Looking back, CEO Renee Aguiar-Lucander is relieved the Stockholm, Sweden-based company began executing its commercialization strategy relatively early. “We started in late 2018, beginning of 2019, so I’ve met the senior team in the US,” she told Scrip in a recent interview

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

 
• By Andrew McConaghie

Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

REGENCY Dandy for Roche In Lupus Nephritis

 
• By Elizabeth Cairns

Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.    

AstraZeneca Believes Size Matters In Amyloidosis

 
• By Elizabeth Cairns

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.    

Pfizer And Flagship’s Quotient To Seek Out New Heart And Kidney Drugs

 
• By Andrew McConaghie

The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.